Abstract
A case series reported promising findings for a 27mer H3K27M targeted peptide vaccine in 8 patients with diffuse midline glioma (DMG). This was a report from a compassionate access program delivering a first-in-human therapy to patients with recurrent disease. DMG, typically presenting in children and young adults, is a highly aggressive primary tumor within the central nervous system; however, unfortunately there are no proven effective systemic therapies for DMG, and it remains an incurable cancer. This deadly tumor typically occurs in the midline structures of the brain and is characterized by a mutation in K27M genes, which produces a tumor antigen that can be targeted for vaccination strategies.